Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis

Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis: A Prospective Cross Over Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00152711

Enrollment

Registered

2005-09-09

Start date

2004-09-30

Completion date

Unknown

Last updated

2007-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Steatohepatitis, Sleep Apnea Syndrome

Brief summary

This study aims to evaluate the impact of nasal continuous positive airway pressure (nCPAP) treatment on liver enzymes in patients with sleep apnea syndrome and nonalcoholic steatohepatitis. Using a cross over design, the evolution of liver enzymes will be evaluated in 40 patients during a consecutive period of 6 weeks, with and without nCPAP treatment.

Interventions

DEVICEnCPAP

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* 18 to 70 years old * Nonalcoholic steatohepatitis proven by liver biopsy * Sleep apnea syndrome proven by polysomnography with an apnea-hypopnea index \> 10 events/hour * Informed consent

Exclusion criteria

* Psychiatric disorder * Other cause of liver disease * Professional driver

Countries

France

Contacts

Primary ContactFrédéric Gagnadoux, MD

frgagnadoux@chu-angers.fr33(0)241353695

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026